Skip to main content
Fig. 3 | Systematic Reviews

Fig. 3

From: Efficacy and safety of duloxetine in painful diabetic peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials

Fig. 3

Quality of life. A Mean improvement in patients’ scores on the Short Form-36 (SF-36) physical functioning domain at ≤ 12 weeks. B Mean improvement in patients’ scores on the SF-36 mental health domain at ≤ 12 weeks. C Mean improvement in patients’ scores on SF-36 bodily pain domain at ≤ 12 weeks. D Patients’ scores on the Patient Global Impression of Improvement scale at ≤ 12 weeks. E Mean improvement in patients’ scores on the Brief Pain Inventory (interference) scale: average of the scores on 7 items at ≤ 12 weeks. F Mean improvement in patients’ scores on the Clinical Global Impression severity subscale at ≤ 12 weeks. G Mean improvement in patients’ scores on the European Quality of Life Instrument 5D version at ≤ 12 weeks. H Mean improvement in patients’ scores on the Short-Form McGill Pain Questionnaire sensory component at ≤ 12 weeks

Back to article page